Introduction

Irritable bowel syndrome (IBS) is one of the most common and clinically significant functional gastrointestinal disorders in children and adolescents. Classified as category H2b under the Rome IV system (2016), it belongs to the broader group of functional abdominal pain disorders (FAPDs) in the pediatric population. The defining feature of IBS is recurrent abdominal pain that is temporally associated with changes in bowel habits: defecation, stool frequency, or stool form. This association with bowel function distinguishes IBS from other FAPDs such as functional dyspepsia (upper abdominal symptoms not related to defecation), abdominal migraine (paroxysmal episodes with intervening wellness), and functional abdominal pain not otherwise specified (FAP-NOS).

The Rome IV criteria for pediatric IBS represent an important evolution from earlier iterations. Key changes include the removal of "discomfort" as a qualifying symptom (retaining only "pain"), a revised frequency threshold, the formal addition of a constipation distinction criterion, and adoption of a positive diagnostic approach that does not require exhaustive exclusion of organic disease. These refinements reflect growing evidence about the nature of IBS as a disorder of gut-brain interaction, driven by visceral hypersensitivity, altered motility, central sensitization, microbiome changes, and psychological factors rather than a single structural abnormality.

The clinical impact of pediatric IBS is substantial. Beyond the physical symptoms of pain and altered bowel habits, IBS in children is associated with significant impairment in quality of life, school attendance, social functioning, and family well-being. Early, confident diagnosis and multimodal management can meaningfully improve outcomes.

Historical Background: Evolution of Pediatric IBS Criteria

The conceptualization and diagnostic criteria for IBS in children have undergone substantial revision across successive Rome iterations.

Rome II (1999) first defined pediatric IBS as a distinct entity, borrowing heavily from the adult Manning criteria and Rome I framework. The criteria required abdominal discomfort or pain with features related to defecation and stool changes, but the requirements were relatively broad and the distinction from other forms of recurrent abdominal pain was not always clear.

Rome III (2006) refined the pediatric IBS definition considerably. It required "abdominal discomfort or pain" associated with two or more of three bowel-related features (improvement with defecation, onset associated with a change in stool frequency, onset associated with a change in stool form). Symptoms needed to occur at least once per week for at least two months. The inclusion of "discomfort" alongside "pain" was intended to capture milder presentations, but it introduced ambiguity, as "discomfort" proved difficult to define consistently, particularly in younger children. IBS subtype classification (IBS-C, IBS-D, IBS-M, IBS-U) based on the Bristol Stool Form Scale was available but not heavily emphasized in pediatric practice.

Rome IV (2016) introduced several pivotal changes. "Discomfort" was removed; only "pain" qualifies. The frequency threshold was changed from "at least once per week" to "at least 4 days per month" (functionally similar but more precise). The bowel-related association requirement was simplified: pain must be associated with at least one (rather than two) of three features (related to defecation, change in stool frequency, change in stool form). A critically important new criterion was added: in children with constipation, the pain must not resolve with resolution of the constipation; if it does, the diagnosis is functional constipation, not IBS. The exclusion criterion was reworded to support positive diagnosis with selective testing.

Diagnostic Criteria

The Rome IV diagnostic criteria for irritable bowel syndrome in children (H2b) require that all of the following be fulfilled for at least 2 months before diagnosis:

#	Criterion	Requirement
1	Abdominal pain frequency and bowel association	Abdominal pain at least 4 days per month associated with one or more of: (a) related to defecation, (b) a change in frequency of stool, (c) a change in form (appearance) of stool
2	Constipation distinction	In children with constipation, the pain does not resolve with resolution of the constipation. If pain resolves when constipation is treated, the diagnosis is functional constipation (H3a), not IBS.
3	Exclusion of organic disease	After appropriate evaluation, the symptoms cannot be fully explained by another medical condition
4	Duration	Criteria fulfilled for at least 2 months before diagnosis

Criterion 1: Abdominal Pain with Bowel-Related Associations

This is the central, defining criterion for IBS. It has two components that must both be present:

Pain frequency: Abdominal pain must occur on at least 4 days per month. The removal of "discomfort" means that only pain qualifies. Rome IV defines pain as an unpleasant sensory experience that is clearly identifiable as hurting. Children must be able to distinguish pain from other sensations (pressure, fullness, bloating) for this criterion to be reliably assessed. In younger children, parental observation of pain behaviors (facial grimacing, clutching the abdomen, cessation of activity) may supplement self-report.

Bowel-related association: The pain must be associated with at least one of three bowel-related features:

• Related to defecation: The pain increases or improves with bowel movements. The Rome IV criteria deliberately use "related to" rather than the earlier "improved by" to acknowledge that in some children, defecation worsens rather than relieves the pain (a pattern more commonly seen in IBS-C).
• A change in frequency of stool: The child experiences noticeably more frequent or less frequent bowel movements compared to baseline during symptomatic periods. This includes both increased frequency (suggesting diarrhea-pattern IBS) and decreased frequency (suggesting constipation-pattern IBS).
• A change in form (appearance) of stool: The consistency or appearance of stool changes during symptomatic periods, assessed using the Bristol Stool Form Scale (BSS). Changes may include harder stools (BSS types 1-2), looser stools (BSS types 6-7), or alternating between the two.

Only one of the three bowel-related associations needs to be present. This is a relaxation from Rome III, which required two of three, and it reflects evidence that requiring multiple associations can exclude children with genuine IBS who predominantly exhibit only one bowel-related feature.

Criterion 2: The Constipation Distinction

This is a new and critically important criterion introduced in Rome IV. It addresses a long-standing source of diagnostic confusion: the overlap between IBS with constipation (IBS-C) and functional constipation (H3a). Both conditions involve abdominal pain and constipation, and distinguishing between them has significant therapeutic implications.

The principle is straightforward: if the child has constipation and the abdominal pain resolves completely when the constipation is adequately treated (with laxatives, dietary measures, or behavioral interventions), then the pain was a consequence of the constipation rather than an independent IBS symptom. In this case, the correct diagnosis is functional constipation, not IBS. If the pain persists despite adequate resolution of constipation, IBS is the appropriate diagnosis.

This criterion requires clinical follow-up. At the initial evaluation, it may not be possible to determine whether pain will resolve with constipation treatment. In practice, a reasonable approach is to treat the constipation first and reassess: if pain resolves, the diagnosis is functional constipation; if pain persists, IBS should be diagnosed.

Criterion 3: Exclusion of Organic Disease

The Rome IV phrasing "after appropriate evaluation, the symptoms cannot be fully explained by another medical condition" is deliberate. It supports making a positive, confident diagnosis based on symptom pattern and the absence of alarm features, without mandating a specific battery of tests. In a child with a characteristic IBS presentation and no alarm features, a careful history and physical examination may constitute adequate evaluation. This approach reduces unnecessary investigations, lowers healthcare costs, and avoids reinforcing illness behavior through repeated testing.

Criterion 4: Duration

The 2-month duration requirement ensures that only chronic, established symptom patterns are classified as IBS. This threshold reduces the risk of misclassifying transient bowel disturbances (e.g., post-infectious, dietary, or stress-related symptoms) as a chronic functional disorder. The 2-month requirement is unchanged from Rome III.

IBS Subtype Classification

Once the diagnosis of IBS is established, Rome IV recommends subtype classification based on the predominant bowel habit pattern, assessed using the Bristol Stool Form Scale (BSS). Subtype classification guides management decisions and facilitates research enrollment.

Subtype	Abbreviation	Stool Pattern (Bristol Stool Scale)
Constipation predominant	IBS-C	More than 25% of bowel movements are BSS types 1-2 (hard/lumpy) AND less than 25% are BSS types 6-7 (loose/watery)
Diarrhea predominant	IBS-D	More than 25% of bowel movements are BSS types 6-7 (loose/watery) AND less than 25% are BSS types 1-2 (hard/lumpy)
Mixed bowel habits	IBS-M	More than 25% of bowel movements are BSS types 1-2 AND more than 25% are BSS types 6-7
Unsubtyped	IBS-U	Meets IBS diagnostic criteria but bowel habit pattern cannot be accurately classified into IBS-C, IBS-D, or IBS-M

Subtype classification should be based on stool form on days when stools are abnormal, not on all days. A stool diary maintained for at least 2 weeks, with the child or parent recording each bowel movement using the Bristol Stool Form Scale, is the most reliable method for subtype determination.

The Bristol Stool Form Scale

The Bristol Stool Form Scale (BSS) is a validated visual tool that classifies stool into seven types based on form and consistency:

BSS Type	Description	Clinical Interpretation
Type 1	Separate hard lumps (like nuts)	Severe constipation
Type 2	Sausage-shaped but lumpy	Mild constipation
Type 3	Sausage-shaped with cracks on surface	Normal
Type 4	Smooth, soft sausage or snake	Normal (ideal)
Type 5	Soft blobs with clear-cut edges	Tending toward diarrhea
Type 6	Fluffy pieces with ragged edges, mushy	Mild diarrhea
Type 7	Entirely liquid, no solid pieces	Severe diarrhea

A modified Bristol Stool Form Scale for children (mBSFS-C) is available and uses child-friendly illustrations. It may improve the accuracy of stool form reporting in younger children. For IBS subtyping purposes, BSS types 1-2 are classified as constipation-pattern stools and types 6-7 as diarrhea-pattern stools.

Subtype Instability

It is important to recognize that IBS subtypes can shift over time. A child initially classified as IBS-C may later develop IBS-D or IBS-M, and vice versa. Studies in adults suggest that approximately one-third of IBS patients change subtype over a 1-year period. While pediatric-specific data on subtype stability are limited, clinical experience suggests similar variability. Periodic reassessment with a stool diary is recommended, particularly when symptoms change or management needs to be adjusted.

Rome IV Functional Abdominal Pain Disorders in Children

IBS is one of four functional abdominal pain disorders (FAPDs) defined by Rome IV for children and adolescents. Understanding the broader FAPD classification is essential for accurate differential diagnosis within the functional spectrum.

Category	Disorder	Key Distinguishing Features
H2a	Functional dyspepsia	Postprandial fullness, early satiation, or epigastric pain/burning localized to the upper abdomen, not associated with defecation
H2b	Irritable bowel syndrome (IBS)	Abdominal pain associated with defecation or changes in stool frequency/form
H2c	Abdominal migraine	Paroxysmal episodes of intense periumbilical or midline abdominal pain lasting at least 1 hour, with intervening periods of usual health
H2d	Functional abdominal pain, not otherwise specified (FAP-NOS)	Episodic or continuous abdominal pain that does not meet criteria for FD, IBS, or abdominal migraine

Rome IV acknowledges that more than one FAPD can coexist in the same patient. A child who has IBS symptoms (pain associated with defecation and stool changes) and also has upper abdominal symptoms meeting functional dyspepsia criteria (postprandial fullness, epigastric burning not related to defecation) may carry both diagnoses simultaneously. Studies suggest that 30% to 50% of children meeting criteria for one FAPD also meet criteria for at least one additional FAPD.

Changes from Rome III to Rome IV

Feature	Rome III (2006)	Rome IV (2016)
Symptom terminology	"Abdominal discomfort or pain"	"Abdominal pain" only ("discomfort" removed)
Frequency threshold	At least once per week	At least 4 days per month
Bowel-related association	Two or more of three features required	One or more of three features required
Bowel-related feature wording	"Improvement with defecation," "onset associated with change in stool frequency," "onset associated with change in stool form"	"Related to defecation," "a change in frequency of stool," "a change in form of stool"
Constipation distinction	Not explicitly addressed	Explicitly states: if pain resolves with constipation treatment, the diagnosis is functional constipation (H3a), not IBS
Duration requirement	At least 2 months	At least 2 months (unchanged)
Organic disease exclusion	"No evidence of organic disease"	"After appropriate evaluation, symptoms cannot be fully explained by another medical condition"
Diagnostic philosophy	Primarily exclusionary	Positive, criteria-based diagnosis with selective testing

The removal of "discomfort" is clinically significant. "Discomfort" was considered too vague and inconsistently interpreted across cultures, languages, and developmental stages. By restricting the criterion to "pain," Rome IV aims for greater diagnostic specificity, though this may exclude some children with genuine IBS who describe their symptoms as "discomfort" or "not feeling right" rather than "pain." Clinicians should use judgment in interpreting symptom reports from young children.

The change in bowel-related association wording is important. Rome III used directional language: "improvement" with defecation, "onset associated with" stool changes. Rome IV uses non-directional language: "related to" defecation, "a change in" stool. This acknowledges that in some children, defecation worsens pain (common in IBS-C where straining against hard stools increases discomfort), and that changes in stool do not necessarily coincide with pain onset but may be temporally correlated in other ways.

The reduction from requiring two bowel-related associations to one broadens the diagnostic net. Under Rome III, a child whose pain was clearly related to defecation but who had no notable change in stool frequency or form could not be diagnosed with IBS. Rome IV corrects this by recognizing that a single bowel-related association is sufficient when combined with the other criteria.

Epidemiology

• Worldwide prevalence: IBS is one of the most common FAPDs in children and adolescents. Worldwide pooled prevalence estimates range from approximately 6% to 14% depending on the criteria used and the population studied. A meta-analysis of pediatric functional abdominal pain disorders found that IBS (using various Rome criteria) was among the most frequently diagnosed FAPDs globally.
• Effect of criteria version: Studies directly comparing Rome III and Rome IV in the same population consistently find that Rome IV criteria identify somewhat fewer children with IBS than Rome III. This is primarily because of the removal of "discomfort" and the more restrictive requirement for pain. In one large comparative study, IBS prevalence dropped from approximately 5.1% under Rome III to 2.8% under Rome IV in the same cohort.
• Sex distribution: IBS in children shows a slight female predominance, particularly in the adolescent age group. This mirrors the well-established female predominance in adult IBS. Prepubertal sex ratios are more balanced.
• Age of onset: Peak onset occurs during school-age and adolescent years. IBS is less commonly diagnosed in children under 4 to 5 years, partly because younger children have difficulty articulating the relationship between pain and bowel habits, and partly because functional constipation is the more common presentation in this age group.
• Subtype distribution: In pediatric cohorts, IBS-C is the most commonly reported subtype, followed by IBS-M and IBS-D. IBS-U is relatively uncommon when a stool diary is used for classification. Subtype distribution may differ across populations and age groups.
• Impact on quality of life: Children with IBS report significantly lower health-related quality of life compared to healthy peers and even compared to children with other chronic conditions. School absenteeism, reduced participation in extracurricular activities, sleep disruption, and family disruption are common. The economic burden includes direct medical costs (clinic visits, investigations, medications) and indirect costs (parental work absence, school accommodation needs).
• Persistence into adulthood: Longitudinal studies suggest that a substantial proportion of children with IBS continue to have symptoms into adolescence and adulthood. Some transition to adult IBS; others develop different functional gastrointestinal disorders or somatic symptom disorders. Early treatment may modify this trajectory.

Pathophysiology

The pathophysiology of IBS in children is multifactorial and is understood within the framework of disorders of gut-brain interaction. No single mechanism accounts for all presentations; rather, IBS arises from the interaction of peripheral (gastrointestinal) and central (brain and spinal cord) factors, modulated by psychological, immunological, microbial, and environmental influences.

Visceral Hypersensitivity

Visceral hypersensitivity is the most consistently demonstrated pathophysiologic abnormality in pediatric IBS. Children with IBS have lower thresholds for pain perception in response to rectal or colonic balloon distension compared to healthy controls. This means that normal physiological events (gas, peristalsis, stool passage) that are imperceptible or mildly uncomfortable in healthy children are experienced as painful by children with IBS. The hypersensitivity may be peripheral (at the level of the gut wall, involving sensitized enteric nerve endings) or central (at the level of the spinal cord or brain, involving amplified processing of visceral afferent signals), or both.

Altered Intestinal Motility

Abnormal patterns of intestinal motility are demonstrable in subsets of children with IBS and contribute to bowel habit disturbances:

• IBS-D: Accelerated colonic transit, increased frequency of high-amplitude propagated contractions, and reduced colonic water absorption result in loose, frequent stools.
• IBS-C: Delayed colonic transit, reduced frequency of propulsive contractions, and increased colonic water absorption result in hard, infrequent stools.
• IBS-M: Alternating patterns of accelerated and delayed transit may account for the mixed bowel habit.

However, motility abnormalities do not consistently correlate with symptom severity, and many children with IBS have normal transit times. This suggests that motility is one contributory factor but not the sole determinant of symptoms.

Central Sensitization and Altered Brain Processing

Functional neuroimaging studies in adults with IBS have demonstrated altered activation of brain regions involved in pain processing, emotional regulation, and visceral perception, including the anterior cingulate cortex, insula, prefrontal cortex, and amygdala. While pediatric neuroimaging data are limited, the clinical observations that children with IBS have heightened pain responses to rectal distension and that stress and anxiety reliably exacerbate symptoms support a central sensitization model. The descending pain modulatory pathways (which normally suppress visceral pain signals at the spinal cord level) may be impaired in IBS, resulting in reduced pain inhibition.

Gut Microbiome Alterations

The composition and function of the gut microbiome are increasingly recognized as contributors to IBS pathophysiology. Studies in children with IBS have demonstrated:

• Reduced microbial diversity compared to healthy controls
• Alterations in specific bacterial taxa (including reduced Bifidobacterium and Lactobacillus species in some studies)
• Changes in microbial metabolite profiles, including altered short-chain fatty acid production and bile acid metabolism
• Correlation between microbiome composition and specific IBS symptoms or subtypes

The microbiome may influence IBS through effects on mucosal immune function, intestinal permeability, enteric nervous system signaling, bile acid deconjugation, and production of neuroactive metabolites (e.g., serotonin, tryptophan metabolites). However, whether microbiome changes are causative, consequential, or coincidental remains uncertain.

Mucosal Immune Activation and Low-Grade Inflammation

Low-grade mucosal inflammation has been documented in a subset of children with IBS. Increased mast cell numbers and degranulation in the colonic mucosa, particularly in proximity to enteric nerve fibers, have been reported. Mast cell mediators (histamine, tryptase, prostaglandins) can directly activate and sensitize visceral afferent nerves, providing a mechanistic link between mucosal immune activation and visceral hypersensitivity. Increased intestinal permeability ("leaky gut") may allow luminal antigens to reach the submucosal immune compartment, perpetuating this cycle.

Post-Infectious IBS

A well-recognized subset of pediatric IBS develops following an episode of acute infectious gastroenteritis (post-infectious IBS, or PI-IBS). The risk is estimated at 10% to 15% following acute bacterial gastroenteritis. The proposed mechanism involves persistent low-grade mucosal inflammation, increased mucosal permeability, altered microbiome composition, and sensitization of enteric and visceral afferent neural pathways following the infection. PI-IBS may have a somewhat different natural history, with gradual improvement over time in many cases, though some children develop chronic, persistent IBS.

Psychological and Psychosocial Factors

Anxiety, depression, somatization, and adverse life events are strongly associated with IBS in children and adolescents. The relationship is bidirectional through the gut-brain axis:

• Top-down: Psychological distress activates stress response pathways (hypothalamic-pituitary-adrenal axis, autonomic nervous system), which modulate intestinal motility, mucosal immune function, visceral sensitivity, and microbiome composition.
• Bottom-up: Chronic abdominal pain and bowel dysfunction generate psychological distress, school avoidance, social isolation, and impaired self-efficacy, which in turn amplify symptoms through stress-mediated pathways.

Anxiety deserves particular emphasis: it is the most consistently associated psychological comorbidity in pediatric IBS and is a strong predictor of symptom severity, functional disability, and treatment response. Maladaptive cognitive patterns, including pain catastrophizing and fear avoidance, are common and represent important therapeutic targets.

Dietary Factors

Dietary components can trigger or exacerbate IBS symptoms in susceptible children. Fermentable carbohydrates (FODMAPs: fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) are osmotically active and rapidly fermented by colonic bacteria, producing gas, distension, and altered motility. High-FODMAP foods include fructose, lactose, fructans (wheat, onion, garlic), galacto-oligosaccharides (legumes), and polyols (sorbitol, mannitol). A low-FODMAP diet has shown promise in reducing IBS symptoms in adolescents. Other dietary triggers reported by patients include caffeine, spicy foods, fatty foods, and carbonated beverages, though responses are highly individual.

Genetic Factors

Family studies demonstrate that IBS clusters in families, with first-degree relatives of IBS patients having a 2- to 3-fold increased risk. Twin studies suggest both genetic and shared environmental contributions. Candidate genes implicated in IBS include those involved in serotonin metabolism (5-HTTLPR polymorphism), bile acid synthesis, immune regulation, and intestinal barrier function. However, no single gene variant explains more than a small fraction of IBS risk, and the disorder is likely polygenic with significant gene-environment interaction.

Clinical Evaluation

The Rome IV framework supports a positive diagnostic approach to IBS. In most children with a characteristic symptom pattern and no alarm features, a thorough history and focused physical examination are sufficient to make a confident diagnosis.

History

A comprehensive symptom history should address:

• Pain characteristics: Location (typically periumbilical or lower abdominal), frequency, severity, duration of each episode, timing, aggravating factors, and relieving factors
• Bowel-related associations: Does the pain increase or decrease with defecation? Is there a change in stool frequency or consistency during painful episodes? Use of a stool diary with the Bristol Stool Form Scale for at least 2 weeks is strongly recommended.
• Bowel pattern: Frequency of bowel movements, consistency (BSS type), urgency, straining, sensation of incomplete evacuation, fecal incontinence
• Associated symptoms: Bloating, gas, nausea, mucus in stool
• Impact on function: School attendance, participation in activities, sleep quality, social functioning
• Dietary history: Potential triggers (dairy, wheat, high-FODMAP foods), caffeine, carbonated beverages
• Medication history: NSAIDs, antibiotics, laxatives, and response to prior treatments
• Psychosocial history: Anxiety, depression, school-related stressors, bullying, family dynamics, adverse childhood experiences
• Family history: IBS, inflammatory bowel disease, celiac disease, functional GI disorders

Physical Examination

The physical examination in children with IBS is typically normal. A focused examination should include growth parameters (weight, height, BMI plotted on growth curves), abdominal examination for tenderness (typically diffuse or periumbilical without guarding or rebound), distension, organomegaly, and perianal inspection (for fissures, fistulae, or skin tags that might suggest Crohn disease). The presence of localized right lower quadrant or right upper quadrant tenderness, palpable masses, perianal disease, or hepatosplenomegaly should prompt further investigation.

Investigations

In the absence of alarm features, routine laboratory testing is not required. Rome IV supports making a confident diagnosis based on symptom pattern. When testing is pursued based on clinical judgment, commonly considered investigations include:

• Complete blood count, ESR/CRP (to screen for inflammation or anemia)
• Celiac serologies (tissue transglutaminase IgA with total IgA), recommended in all children with IBS-D or IBS-M given the 4- to 5-fold higher prevalence of celiac disease in patients with IBS-type symptoms
• Fecal calprotectin (to differentiate functional from inflammatory bowel disease; a normal level significantly reduces the probability of IBD)
• Stool studies (ova and parasites, Giardia antigen) if infectious etiology is suspected
• Thyroid function tests if clinically indicated

Alarm Features Warranting Further Investigation

The following red flag features should prompt additional evaluation to exclude organic disease before applying the IBS diagnosis:

• Involuntary weight loss or faltering growth
• Deceleration of linear growth or delayed puberty
• Persistent vomiting (especially bilious)
• Chronic severe diarrhea (especially nocturnal diarrhea)
• Gastrointestinal blood loss (hematemesis, hematochezia, melena, occult blood)
• Unexplained fever
• Family history of inflammatory bowel disease or celiac disease
• Pain that consistently awakens the child from sleep
• Perianal disease (fistula, fissure, abscess, skin tags)
• Arthritis or unexplained rashes
• Abnormal laboratory findings (elevated ESR/CRP, anemia, hypoalbuminemia, elevated fecal calprotectin)

The presence of alarm features does not automatically establish an organic diagnosis but shifts the pretest probability sufficiently to warrant targeted investigation. In particular, the combination of recurrent abdominal pain with weight loss, bloody stools, or elevated inflammatory markers should raise strong suspicion for inflammatory bowel disease.

Differential Diagnosis

Category	Conditions
Inflammatory	Crohn disease, ulcerative colitis, celiac disease, microscopic colitis
Infectious	Giardiasis, post-infectious IBS, Clostridioides difficile, small intestinal bacterial overgrowth (SIBO)
Functional (other FAPDs)	Functional constipation (H3a; if pain resolves with constipation treatment), functional dyspepsia (H2a), abdominal migraine (H2c), FAP-NOS (H2d)
Dietary	Lactose intolerance, fructose malabsorption, food allergy or sensitivity
Endocrine/metabolic	Hypothyroidism, hyperthyroidism, diabetes mellitus
Anatomic	Malrotation, internal hernia, adhesive disease (postoperative)
Gynecological (adolescent females)	Endometriosis, ovarian pathology, dysmenorrhea
Medication-related	NSAID enteropathy, antibiotic-associated diarrhea, laxative overuse

The distinction between IBS-C and functional constipation is the most common intra-functional differential diagnostic challenge and is addressed directly by the Rome IV constipation distinction criterion (criterion 2). Celiac disease deserves particular emphasis because it can present with symptoms indistinguishable from IBS (abdominal pain, bloating, altered bowel habits), and serological screening is widely recommended in children with IBS-type symptoms, particularly IBS-D and IBS-M.

Management Considerations

Management of pediatric IBS is multimodal, integrating education, psychological interventions, dietary modification, and pharmacological therapy. The evidence base for treatment of IBS in children is growing but remains more limited than in adults. No medication is specifically approved for pediatric IBS.

Education and Reassurance

Clear, empathetic education is the foundation of management. Families should understand that IBS is a real, recognized medical condition caused by altered gut-brain communication, not by a structural abnormality. The biopsychosocial model should be explained in age-appropriate terms: the gut and the brain are in constant communication, and in IBS this communication is amplified, leading to increased pain perception and altered bowel function. Making a positive diagnosis confidently, rather than framing IBS as a diagnosis of exclusion, reduces family anxiety and discourages the pursuit of unnecessary investigations.

Psychological Interventions

Psychological interventions are considered first-line therapy for pediatric IBS, with the strongest evidence base of any treatment modality:

Intervention	Evidence Level	Details
Cognitive behavioral therapy (CBT)	Strong	The best-studied psychological intervention for pediatric IBS. CBT targets maladaptive cognitions (catastrophizing, fear of symptoms), behavioral avoidance (school refusal, activity restriction), and coping strategies. Multiple RCTs demonstrate significant improvement in pain, disability, and quality of life. Internet-delivered CBT programs have also shown efficacy.
Gut-directed hypnotherapy	Strong	Gut-directed hypnotherapy targets visceral sensations, motility, and gut-brain communication through guided imagery and suggestion. Randomized trials in children with functional abdominal pain and IBS have demonstrated significant and sustained benefit, with treatment effects persisting at 1- to 5-year follow-up.
Mindfulness-based interventions	Emerging	Mindfulness meditation and acceptance-based approaches may reduce symptom-related distress and improve coping. The evidence base in pediatric IBS is growing but less established than for CBT or hypnotherapy.

Dietary Modifications

Approach	Target Subtype	Details
Low-FODMAP diet	All subtypes (especially IBS-D, IBS-M)	A supervised low-FODMAP diet, implemented with dietitian guidance through elimination (2-6 weeks) and structured reintroduction phases, has shown symptom improvement in adolescents with IBS. Must be supervised to avoid nutritional deficiencies, particularly in growing children.
Fiber supplementation	IBS-C	Soluble fiber (e.g., psyllium, partially hydrolyzed guar gum) may improve stool consistency and reduce pain in IBS-C. Insoluble fiber (e.g., wheat bran) is less effective and may exacerbate bloating and gas.
Lactose and fructose reduction	IBS-D, IBS-M	A trial reduction of lactose (dairy) or excess fructose may benefit children with suspected carbohydrate malabsorption contributing to IBS symptoms.
General dietary advice	All subtypes	Regular meal timing, adequate hydration, avoidance of known personal triggers (caffeine, carbonated drinks, spicy or fatty foods). A food-symptom diary can help identify individual triggers.

Probiotics

Some evidence supports the use of specific probiotic strains for improving symptoms in pediatric IBS, though data are strain-specific and not universally positive:

• Lactobacillus rhamnosus GG: The most studied probiotic in pediatric functional abdominal pain. Some trials show improvement in pain frequency, though results are not uniform across all studies.
• VSL#3 (now Visbiome): A multi-strain probiotic that has shown benefit in some pediatric IBS studies, particularly for bloating and flatulence.

Probiotics should be considered as adjunctive therapy rather than monotherapy. The response is strain-specific, and benefits observed with one strain cannot be assumed to apply to others. Duration of benefit after discontinuation is uncertain.

Pharmacological Therapy

Agent	Target	Notes
Antispasmodics (hyoscyamine, dicyclomine)	Pain, cramping	May provide short-term relief of cramping and spasm. Evidence in pediatric IBS is limited. Used as needed rather than scheduled.
Peppermint oil (enteric-coated)	Pain, bloating	Acts as a smooth muscle relaxant. Some evidence of benefit in pediatric IBS for reducing pain frequency and severity. Generally well tolerated.
Osmotic laxatives (PEG 3350)	IBS-C (bowel habit)	First-line for managing the constipation component of IBS-C. Important to note that laxatives address bowel habit but not the IBS pain component. If pain resolves with laxatives alone, reconsider functional constipation rather than IBS.
Loperamide	IBS-D (bowel habit)	Reduces stool frequency and urgency in IBS-D. Does not improve pain. Used as needed for diarrhea management, not as scheduled therapy.
Low-dose tricyclic antidepressants (amitriptyline, nortriptyline)	Refractory pain	Neuromodulators that may reduce visceral hypersensitivity and modulate central pain processing. Typically started at low doses (0.1-0.2 mg/kg/day) and titrated. ECG recommended before initiation. Benefit may take 4 to 8 weeks. Evidence is extrapolated primarily from adult trials.
Cyproheptadine	Pain, nausea	Antihistamine with antiserotonergic properties. Commonly used in younger children. May improve pain and associated nausea. Retrospective data support safety and some efficacy.

Interpreting Criteria Results

When applying the Rome IV criteria for child IBS, the diagnostic evaluation has two components that must both be satisfied:

Core Criteria (All Must Be Met)

1. Pain frequency: Abdominal pain at least 4 days per month
2. Constipation distinction: In children with constipation, pain does not resolve with resolution of constipation
3. Exclusion: After appropriate evaluation, symptoms cannot be fully explained by another medical condition
4. Duration: Criteria fulfilled for at least 2 months

Bowel-Related Association (At Least One Must Be Met)

• Pain is related to defecation
• A change in frequency of stool
• A change in form (appearance) of stool

If all four core criteria are met AND at least one bowel-related association is present, the patient fulfills the Rome IV criteria for child IBS. Subtype classification (IBS-C, IBS-D, IBS-M, IBS-U) should then be applied based on the predominant bowel pattern using the Bristol Stool Form Scale.

If criteria are not met, clinicians should consider:

• Whether the pain frequency or duration threshold has not yet been reached (and the patient may qualify on reassessment)
• Whether pain resolves with constipation treatment, indicating functional constipation (H3a) rather than IBS
• Whether the pain is better characterized by another FAPD (functional dyspepsia if localized to the epigastrium and not related to defecation; abdominal migraine if episodic with intervening wellness; FAP-NOS if no specific pattern is identified)
• Whether organic causes should be investigated based on the presence of alarm features

Limitations

• Symptom-based diagnosis: The criteria rely entirely on patient- or parent-reported symptoms, which are subject to recall bias, perception differences, and developmental limitations. No biomarker exists to confirm or exclude IBS. This inherently limits diagnostic precision.
• Removal of "discomfort": While intended to improve specificity, removing "discomfort" may exclude some children with genuine IBS who describe their abdominal symptoms using terms other than "pain." Young children in particular may lack the vocabulary to distinguish "pain" from "discomfort," "pressure," or "not feeling right."
• Overlap with functional constipation: Distinguishing IBS-C from functional constipation remains the most challenging intra-functional diagnostic decision. The constipation distinction criterion (does pain resolve with constipation treatment?) requires a therapeutic trial and follow-up, which is not always practical at the initial encounter.
• Age-related challenges: Younger children (under 7 to 8 years) may have difficulty describing the temporal relationship between pain and bowel habits, making it difficult to reliably assess the bowel-related association criteria. Parental observation and stool diaries are essential in this age group but introduce proxy reporting bias.
• Temporal requirements may delay diagnosis: The 2-month duration requirement means that a definitive IBS diagnosis cannot be made at the initial presentation, even when the clinical picture is classic. This can create a period of diagnostic uncertainty for the family.
• Subtype instability: IBS subtypes can change over time, limiting the utility of a single time-point subtype classification for long-term management planning. Periodic reassessment is recommended but not always performed.
• Limited treatment evidence: While the evidence base for psychological interventions in pediatric IBS is relatively strong, evidence for pharmacological therapies is limited. Most drug recommendations are extrapolated from adult data or based on small pediatric studies. No medication is specifically approved for pediatric IBS.
• Cultural variation: Perceptions of normal bowel habits, pain thresholds, and symptom reporting patterns vary across cultures. The criteria were developed primarily from data in Western populations and may not equally capture IBS presentations in all cultural contexts.

Practice Caveats

• Rome IV encourages making a positive, confident diagnosis of IBS based on characteristic symptoms rather than through exhaustive exclusion testing. In the absence of alarm features, limited or no testing is appropriate. Communicating the diagnosis with confidence reduces family anxiety and discourages the cycle of repeated, unnecessary investigations.
• The constipation distinction is clinically critical and should be actively assessed in every child with abdominal pain and constipation. If pain resolves entirely with adequate laxative therapy, the correct diagnosis is functional constipation (H3a), not IBS. This has direct treatment implications: functional constipation is managed primarily with laxatives and behavioral interventions, while IBS requires additional attention to pain management, psychological factors, and dietary modification.
• Screen for anxiety and depression in all children evaluated for IBS. Psychological comorbidities are common, strongly influence symptom severity and functional disability, and represent important therapeutic targets. Validated screening tools (e.g., SCARED, GAD-7, PHQ-A) should be integrated into clinical workflow.
• Celiac disease screening (tissue transglutaminase IgA with total IgA) is widely recommended in children with IBS-type symptoms, particularly IBS-D and IBS-M. Celiac disease can present with symptoms indistinguishable from IBS, and serological screening is simple, inexpensive, and highly sensitive.
• Fecal calprotectin is a useful non-invasive screening tool to differentiate IBS from inflammatory bowel disease. A normal fecal calprotectin level has a high negative predictive value for IBD and can help avoid unnecessary colonoscopy.
• IBS subtypes can shift over time. A stool diary using the Bristol Stool Form Scale should be maintained periodically, particularly when symptoms change or when adjusting management strategies.
• Dietary interventions, particularly the low-FODMAP diet, should be implemented under dietitian supervision to avoid nutritional deficiencies in growing children. Unsupervised restrictive diets carry risks of inadequate caloric intake, micronutrient deficiency, and disordered eating behaviors, especially in adolescents.
• Psychological interventions (CBT, gut-directed hypnotherapy) should be positioned as first-line treatments alongside education and dietary management, not reserved as last-resort options for refractory cases. Framing psychological referral as an integral part of comprehensive IBS care rather than an implication that symptoms are "psychological" is essential for family engagement.